Share

Extremely low frequency electromagnetic fields prevent chemotherapy induced myelotoxicity.

PAPER pubmed Electromagnetic biology and medicine 2007 Randomized trial Effect: benefit Evidence: Insufficient

Abstract

Side effects of chemo-radiotherapy reduce the quality and also the survivability of patients. The consequent fatigue and infections, related to myelodepression, act to reduce the dose-intensity of the protocol. Late side effects of chemo-radiotherapy include secondary tumours, acute myeloid leukemias and cardiotoxicity. Side effects of chemotherapy are related to oxidative stress produced by the treatment. Oxidative stress also reduces the efficacy of the treatment. Antioxidative treatment with natural (dietetic) or chemical agents has been reported to reduce the toxicity of chemo-radiotherapy and improve the efficacy of treatment. We here report our experience with SEQEX, an electromedical device that generates Extremely Low Frequency ElectroMagnetic Fields (ELF-EMF) to produce endogenic cyclotronic ionic resonance, to reduce myelotoxicity consequent to ABVD protocol in patients with Hodgkin's lymphoma.

AI evidence extraction

At a glance
Study type
Randomized trial
Effect direction
benefit
Population
Patients with Hodgkin's lymphoma receiving ABVD chemotherapy
Sample size
β€”
Exposure
ELF electromedical device (SEQEX)
Evidence strength
Insufficient
Confidence: 62% Β· Peer-reviewed: yes

Main findings

The authors report experience using the SEQEX device generating ELF-EMF to reduce myelotoxicity consequent to the ABVD protocol in patients with Hodgkin's lymphoma.

Outcomes measured

  • Chemotherapy-induced myelotoxicity / myelodepression

Limitations

  • No quantitative results provided in the abstract
  • Study design details (e.g., randomization, control group) not described in the abstract
  • Exposure parameters (frequency, intensity, duration) not reported
View raw extracted JSON
{
    "study_type": "randomized_trial",
    "exposure": {
        "band": "ELF",
        "source": "electromedical device (SEQEX)",
        "frequency_mhz": null,
        "sar_wkg": null,
        "duration": null
    },
    "population": "Patients with Hodgkin's lymphoma receiving ABVD chemotherapy",
    "sample_size": null,
    "outcomes": [
        "Chemotherapy-induced myelotoxicity / myelodepression"
    ],
    "main_findings": "The authors report experience using the SEQEX device generating ELF-EMF to reduce myelotoxicity consequent to the ABVD protocol in patients with Hodgkin's lymphoma.",
    "effect_direction": "benefit",
    "limitations": [
        "No quantitative results provided in the abstract",
        "Study design details (e.g., randomization, control group) not described in the abstract",
        "Exposure parameters (frequency, intensity, duration) not reported"
    ],
    "evidence_strength": "insufficient",
    "confidence": 0.61999999999999999555910790149937383830547332763671875,
    "peer_reviewed_likely": "yes",
    "keywords": [
        "extremely low frequency",
        "ELF-EMF",
        "SEQEX",
        "electromedical device",
        "cyclotronic ionic resonance",
        "chemotherapy",
        "ABVD",
        "Hodgkin's lymphoma",
        "myelotoxicity",
        "myelodepression",
        "oxidative stress"
    ],
    "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.